Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Akamai Technologies, Inc. (AKAM) vs Philip Morris International Inc. (PM) Price & Performance

Akamai Technologies, Inc.
Philip Morris International Inc.

Price performance

Price movement over the last 24 hours

Key statistics

Akamai Technologies, Inc. vs Philip Morris International Inc. — how do they compare? Akamai Technologies, Inc. trades at $122.51 (market cap $16.63B), while Philip Morris International Inc. trades at $187.79 (market cap $287.96B). The key difference: Philip Morris International Inc. is far larger — about 17.3× Akamai Technologies, Inc.'s market cap, and Philip Morris International Inc. pays a 3.18% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.

AKAMPM
Market Cap
$16.63B$287.96B
Sector
TechnologyConsumer Staples
52-Week High
$161.14$191.86
52-Week Low
$70.53$144.33
Enterprise Value
$21.56B$334.46B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Akamai Technologies, Inc.

Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.

While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.

Philip Morris International Inc.

Philip Morris International (PM) trades at $184.76, up 1.37% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($1.96 vs $1.86 expected) and maintains robust profitability with 26.74% net income margin. Recent news includes a $500 million impairment charge on Canadian operations and updated 2026 guidance, though IQOS brand recognition remains a positive catalyst.

PM offers stable revenue growth and strong cash flow generation, but faces headwinds from currency volatility and illicit market pressures. Analyst consensus remains bullish with $194.25 price target (68% buy ratings), though recent profit forecast cuts and high debt levels warrant caution for risk-averse investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Akamai Technologies, Inc.

Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.

Read more on AKAM

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM